Apellis Pharmaceuticals has secured $328.9M in new capital, a significant infusion for the biotech firm.
This funding round comes as Apellis is now part of Biogen. The acquisition means its independent operations are transitioning, with its dedicated information page slated to cease updates and monitoring in the coming weeks. For the latest news, readers are directed to follow along with Biogen.


















